Your browser doesn't support javascript.
loading
Liver fat as a dietary target by Chinese Medical Nutrition Therapy (CMNT) diet for treating type 2 diabetes with non-alcoholic fatty liver disease: study protocol for a randomised controlled trial.
Luo, Wu; Xiao, Zhiyong; Yang, Xiao; Wu, Ruiyu; Li, Jian; Yu, Zhen; Guo, Shengxiang; Nie, Beibei; Liu, Dongbo.
Afiliación
  • Luo W; College of Biology, Hunan University, Changsha, Hunan, China.
  • Xiao Z; Horticulture College, Hunan Agricultural University, Changsha, Hunan, China.
  • Yang X; Horticulture College, Hunan Agricultural University, Changsha, Hunan, China.
  • Wu R; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
  • Li J; Horticulture College, Hunan Agricultural University, Changsha, Hunan, China.
  • Yu Z; Hunan Provincial Engineering Research Center of Medical Nutrition Intervention Technology for Metabolic Diseases, Changsha, Hunan, China.
  • Guo S; Horticulture College, Hunan Agricultural University, Changsha, Hunan, China.
  • Nie B; Hunan Provincial Engineering Research Center of Medical Nutrition Intervention Technology for Metabolic Diseases, Changsha, Hunan, China.
  • Liu D; Hunan Provincial Engineering Research Center of Medical Nutrition Intervention Technology for Metabolic Diseases, Changsha, Hunan, China.
BMJ Open ; 14(4): e081263, 2024 Apr 29.
Article en En | MEDLINE | ID: mdl-38684277
ABSTRACT

INTRODUCTION:

Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) often coexist and increase risk for developing liver fibrosis and diabetes complications if no effective measures are taken. Dietary intervention is known to be able to achieve diabetes remission, while evidence regarding the long-term effect on liver fat is limited for comorbidity management of type 2 diabetes and NAFLD. This study aims to investigate the long-term effect of a Chinese Medical Nutrition Therapy (CMNT) diet accompanied by intermittent energy restriction on reducing liver fat and glycated haemoglobin (HbA1c) in patients with type 2 diabetes and NAFLD. METHODS AND

ANALYSIS:

This is a multicentre two-armed parallel randomised controlled trial study. 120 participants with type 2 diabetes and NAFLD will be recruited from the physical examination centres of multiple hospitals in China. Participants will be randomly allocated 11 to either the CMNT group or the usual care group. The CMNT group will be instructed to consume the provided specific meal replacement Chinese medicinal foods consisting of 6 cycles of 5 consecutive days followed by 10 days of regular food intake. The usual care group will be given standard dietary advice. Primary outcomes are changes in the controlled attenuation parameter value by transient elastography and HbA1c level. Secondary outcomes include differences in anthropometrics, clinical blood markers, questionnaires, gut microbiota and metabolomics. Further follow-up will be performed at 6 months, 1 year and 2 years. ETHICS AND DISSEMINATION The study protocol was approved by the Biomedical Research Ethics Committee of Hunan Agricultural University (BRECHAU20200235).The results will be disseminated via relevant peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER NCT05439226.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hemoglobina Glucada / Diabetes Mellitus Tipo 2 / Enfermedad del Hígado Graso no Alcohólico País/Región como asunto: Asia Idioma: En Revista: BMJ Open / BMJ open Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hemoglobina Glucada / Diabetes Mellitus Tipo 2 / Enfermedad del Hígado Graso no Alcohólico País/Región como asunto: Asia Idioma: En Revista: BMJ Open / BMJ open Año: 2024 Tipo del documento: Article